Drug Trial Radar · NCT03354897
Clinical Study of UMOD NKCC2 Interaction on Salt-sensitivity in Hypertension
Last checked: Nov 20, 2026Latest source record: Sep 25, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
228
Actual
Start
Apr 5, 2017
Primary completion
Oct 30, 2021
Study completion Oct 30, 2021
Sponsor
- Lead sponsor
- NHS Greater Glasgow and ClydeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Glasgow; British Heart Foundation
- First posted
- Nov 28, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The hypothesis is based on UMOD rs13333226 genotype, there are two strata of hypertensive patients. The High-UMOD group (AA genotype) has increased UMOD excretion, greater salt sensitivity, HTN, normal eGFR and greater BP response to loop diuretics like furosemide. The Low-UMOD group (G allele) has decreased UMOD excretion, salt resistance, increased eGFR, increased proximal tubular reabsorption of Na (possibly related to increased GFR), a poor BP response to loop diuretics, and possibly diminished function of NKCC2. The High-UMOD strata will have decreased delivery of Na+ to the distal tubule and collecting duct because NKCC2 function is normal and the study hypothesis is that the participants will be more responsive to loop diuretics. In contrast, the Low-UMOD group (G allele) will not show a similar response to loop diuretics. This may be related either to lower Na delivery to the TAL, because of increased proximal tubular reabsorption of Na+, or a suppressed function of NKCC2. The population distribution of the High-UMOD group (AA) is 67%. Our overall objective is to test the hypothesis that hypertensive subjects with uncontrolled HTN open possessing the AA genotype of rs13333226 will be better responders to loop diuretics compared to those possessing the G allele.
Conditions
- Cardiovascular Diseases
- Hypertension
Interventions
Torasemide 5Mg TabletDrug
16 weeks treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in ABPMTime frame: 16 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Glasgow Clinical Research Facility
Glasgow, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.